Segall Bryant & Hamill’s Aurinia Pharmaceuticals AUPH Stock Holding History

Segall Bryant & Hamill’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.48M	Buy	263,743 +117,464	+80%	+$1.88M	0.05%	331
2026 Q1	$2.17M	Sell	146,279 -53	-0%	-$775	0.03%	414
2025 Q4	$2.33M	Buy	146,332 +560	+0.4%	+$7.94K	0.03%	409
2025 Q3	$1.61M	Sell	145,772 -1,082	-0.7%	-$11.8K	0.02%	457
2025 Q2	$1.24M	Sell	146,854 -221,933	-60%	-$1.78M	0.02%	484
2025 Q1	$2.97M	Sell	368,787 -148,090	-29%	-$1.2M	0.05%	377
2024 Q4	$4.64M	Sell	516,877 -45,898	-8%	-$374K	0.06%	342
2024 Q3	$4.13M	Buy	562,775 +9,031	+2%	+$56K	0.06%	356
2024 Q2	$3.16M	Buy	+553,744	New	+$2.92M	0.06%	339

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segall Bryant & Hamill's AUPH Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Aurinia Pharmaceuticals (AUPH) stake by 80% in Q2 2026, buying an estimated $1.88M and bringing the position to 263,743 shares worth $4.48M. The position accounts for 0.05% of the portfolio, ranked #331.

Segall Bryant & Hamill first reported a position in AUPH in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.64M in Q4 2024. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Segall Bryant & Hamill held 263,743 shares of Aurinia Pharmaceuticals worth $4.48M as of Q2 2026.
Segall Bryant & Hamill bought 117,464 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $1.88M.
Aurinia Pharmaceuticals made up 0.05% of Segall Bryant & Hamill's portfolio in Q2 2026, its #331 holding.
Segall Bryant & Hamill first reported a position in Aurinia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Segall Bryant & Hamill's Aurinia Pharmaceuticals position peaked at $4.64M in Q4 2024.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.